Related Experiment Video
Updated: Sep 4, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.4K
Shenmai Injection Improves Hypertensive Heart Failure by Inhibiting Myocardial Fibrosis via TGF-β 1/Smad Pathway
Si-Yuan Hu1,2, Yao Zhou3, Sen-Jie Zhong4
1School of Sports Art, Hunan University of Chinese Medicine, Changsha, 410208, China.
Chinese Journal of Integrative Medicine
|July 15, 2022
Summary
Shenmai Injection effectively treats hypertensive heart failure by inhibiting myocardial fibrosis. This treatment improves heart function and reduces fibrosis through the TGF-β1/Smad signaling pathway.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Integrative Medicine
Background:
- Hypertensive heart failure is characterized by significant myocardial fibrosis, a key pathological manifestation.
- Existing treatments may not fully address the underlying fibrotic processes contributing to heart failure progression.
Purpose of the Study:
- To investigate the therapeutic effects of Shenmai Injection (SMI) on hypertensive heart failure in a rat model.
- To elucidate the mechanism by which SMI inhibits myocardial fibrosis, focusing on the TGF-β1/Smad signaling pathway.
Main Methods:
- Salt-sensitive rats were induced with hypertension and heart failure via a high-salt diet.
- Model rats were treated with Shenmai Injection (SMI) or pirfenidone (PFD) and compared to a heart failure (HF) group.
- Cardiac function, blood pressure, myocardial fibrosis, and molecular markers (Col I, TGF-β1, Smad2/3) were assessed using echocardiography, ELISA, histology, and qPCR.
Main Results:
- High-salt diet significantly increased blood pressure, reduced cardiac function (LVEF, LVFS), and induced myocardial fibrosis and inflammation.
- Shenmai Injection treatment significantly improved cardiac function (LVEF, LVFS) and reduced myocardial fibrosis compared to the HF group.
- SMI downregulated the expression of collagen type I (Col I), transforming growth factor β 1 (TGF-β1), Smad2, and Smad3 at both mRNA and protein levels.
Conclusions:
- Myocardial fibrosis is a critical factor in hypertensive heart failure.
- Shenmai Injection demonstrates significant efficacy in improving heart function and inhibiting myocardial fibrosis in this model.
- The therapeutic effect of SMI is mediated by the regulation of the TGF-β1/Smad signaling pathway.
Keywords:
Shenmai Injectionheart failurehypertensionmyocardial fibrosistransforming growth factor β 1/smadMore Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
530
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
534
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
501
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
501
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Heart Failure II: Pathophysiology
31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
01:22Heart Failure Drugs: Diuretics
476
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
476
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
01:22Heart Failure Drugs: β-Blockers
429
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
429